Cancer-associated bone disease.
Patients with cancer are at risk for many events involving the skeleton, including metastatic disease of bone and treatment-related bone loss. Cancer-related therapies that can affect bone include hormonal therapy, chemotherapy, and the use of glucocorticoids. Screening for bone loss, with lifestyle modifications and the early use of anti-osteoporosis therapies such as bisphosphonates, may decrease bone loss and reduce the risk of fracture. This article reviews risk factors and mechanisms associated with cancer-related bone loss and metastases as well as strategies for the detection of bone-related complications of cancer and therapies to treat these complications. This article focuses on the more common cancers with adverse skeletal effects: breast cancer, prostate cancer, and multiple myeloma.
Brown
Sue A
SA
Department of Medicine, University of Virginia,P.O. Box 801420, Charlottesville, VA 22908, USA. sab2f@virginia.edu
Guise
Theresa A
TA
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001851:Bone Diseases, Metabolic / Q000209:etiology*; D001859:Bone Neoplasms / Q000556:secondary*; D001862:Bone Resorption / Q000209:etiology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology
D000970:Antineoplastic Agents